Phase 1 B-NHL Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
B-cell Non-Hodgkins Lymphoma (B-NHL)
Regeneron Pharmaceuticals91 enrolled20 locationsNCT05685173
Recruiting
Phase 1Phase 2
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Acute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaB-Non Hodgkin Lymphoma+2 more
National Cancer Institute (NCI)126 enrolled1 locationNCT05442515
Recruiting
Phase 1
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
Non-Hodgkin LymphomaMantle Cell Lymphoma (MCL)CNS Lymphoma+1 more
University of Colorado, Denver68 enrolled1 locationNCT05098613
Recruiting
Phase 1Phase 2
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
B-cell Non-Hodgkin Lymphoma (B-NHL)
Cellectis S.A.80 enrolled10 locationsNCT05607420
Recruiting
Phase 1Phase 2
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
AML (Acute Myelogenous Leukemia)Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting
Phase 1
An Evaluation of LY007 Cell Injection for r/r B-NHL
B-NHL
Ruijin Hospital18 enrolled1 locationNCT06364852
Recruiting
Phase 1
An Evaluation of LY007 Cell Injection for r/r B-NHL
B-NHL
Shanghai Longyao Biotechnology Inc., Ltd.18 enrolled1 locationNCT06279611